Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-16T16:04:53.222Z Has data issue: false hasContentIssue false

Use of high-dose depot neuroleptics

Published online by Cambridge University Press:  02 January 2018

N. Purandare
Affiliation:
University Hospital of South Manchester
L. Aitken
Affiliation:
Stepping Hill Hospital Stockport
P. Joshi
Affiliation:
Stepping Hill Hospital
C. S. Thomas*
Affiliation:
Department of Psychiatry, University Hospital of South Manchester, Manchester M20 8LR
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Aims and methods

To identify and reduce the number of patients receiving depot neuroleptics above the British National Formulary maximum. The medical records were scrutinised and individual consultants were informed of the results.

Results

For the team involved in this audit there was a significant reduction in the prescription of high-dose depot medication, but this did not generalise to other teams.

Clinical implications

Different teams should repeat the audit and a new depot card has been developed.

Information

Type
Original papers
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.